Cash, cash equivalents and marketable securities as of December 31, 2025 were $217.0 million, compared with $36.1 million as of December 31, 2024.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink
- Midday Fly By: Defense stocks surge on Trump budget request
- Immuneering: Phase 2a Strength of Atebimetinib in First-Line Pancreatic Cancer Supports Buy Rating Despite Competitive Overhang
- Closing Bell Movers: Defense stocks surge on Trump military budget comments
- Immuneering reports ‘positive’ survival, safety data from atebimetinib trial